New generic competition in the U.S. always makes a sales organization uneasy because layoffs usually follow. But Hospira's ($HSP) branded sales team faces a double whammy: earlier-than-expected generic foes for their sedative Precedex, allowed by a new FDA decision; and their boss's threat to lay off pretty much everyone if generics actually do come to market. Report